Cite
A phase 2 study of ibrutinib maintenance following first‐line high‐dose methotrexate‐based chemotherapy for elderly patients with primary central nervous system lymphoma.
MLA
Bairey, Osnat, et al. “A Phase 2 Study of Ibrutinib Maintenance Following First‐line High‐dose Methotrexate‐based Chemotherapy for Elderly Patients with Primary Central Nervous System Lymphoma.” Cancer (0008543X), vol. 129, no. 24, Dec. 2023, pp. 3905–14. EBSCOhost, https://doi.org/10.1002/cncr.34985.
APA
Bairey, O., Taliansky, A., Glik, A., Amiel, A., Yust, K. S., Gurion, R., Zektser, M., Porges, T., Sarid, N., Horowitz, N. A., Shina, T. T., Lebel, E., Cohen, A., Geiger, K. R., Raanani, P., Wolach, O., & Siegal, T. (2023). A phase 2 study of ibrutinib maintenance following first‐line high‐dose methotrexate‐based chemotherapy for elderly patients with primary central nervous system lymphoma. Cancer (0008543X), 129(24), 3905–3914. https://doi.org/10.1002/cncr.34985
Chicago
Bairey, Osnat, Alisa Taliansky, Amir Glik, Alexandra Amiel, Katz, Shlomit Yust, Ronit Gurion, Miri Zektser, et al. 2023. “A Phase 2 Study of Ibrutinib Maintenance Following First‐line High‐dose Methotrexate‐based Chemotherapy for Elderly Patients with Primary Central Nervous System Lymphoma.” Cancer (0008543X) 129 (24): 3905–14. doi:10.1002/cncr.34985.